6th independent analysis showing efficacy from the Boulware PEP trial.
This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).
42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97],
p=0.044, for the original trial 3 day specification.
Wiseman et al., 12/2/2020, preprint, 4 authors.
risk of COVID-19 case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of
many trials.